On June 24, 2025, Sangamo Therapeutics announced positive results from the Phase 1/2 STAAR study for their gene therapy isaralgagene civaparvovec (ST-920), reporting a mean annualized eGFR slope of 1.965 mL/min/1.73m²/year in 32 patients at 52 weeks and affirming plans to submit for FDA approval in early 2026. The therapy showed significant clinical benefits for Fabry disease patients, with favorable safety results and improvements in quality of life indicators.